GlassScriptPhysician profile
Gayathri Dasharathy
NPI 1801966338
$1,760.03
in general payments reported to CMS, 2019-2025
20 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $295 · 2021: $238 · 2022: $252 · 2023: $339 · 2024: $271 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $375.62 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Veloxis Pharmaceuticals, INC. | $276.31 | 2022-2025 | Envarsus |
| Takeda Pharmaceuticals U.S.A., INC. | $143.20 | 2019-2025 | Livtencity |
| Sunovion Pharmaceuticals INC. | $137.16 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $135.94 | 2019-2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.20 | 2021-2024 | Caplyta |
| Merck Sharp & Dohme LLC | $93.41 | 2022-2025 | Prevymis |
| Neurocrine Biosciences, INC. | $91.15 | 2021-2024 | Ingrezza |
| Eisai INC. | $78.43 | 2020-2024 | |
| Allergan, INC. | $73.38 | 2019-2020 | |
| Abbvie INC. | $44.99 | 2022-2023 | Vraylar |
| Alexion Pharmaceuticals, INC. | $42.60 | 2023-2024 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.76 | 2025 | Xifaxan |
| Madrigal Pharmaceuticals | $24.53 | 2024 | Resmetirom |
| Vanda Pharmaceuticals INC. | $24.44 | 2025 | Fanapt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.48 | 2024 | Dexcom G6 Transmitter |
| Kci USA, INC. | $20.96 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.19 | 2022 | |
| Calliditas Therapeutics US INC. | $13.28 | 2022 | |
| Acadia Pharmaceuticals INC | $13.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gayathri Dasharathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.